The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
In 2024, the FDA approved 50 novel drugs ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical ... announced today the FDA has approved a supplemental New Drug Application (sNDA) for ...
Johnson & Johnson JNJ announced that the FDA has issued a complete response letter (“CRL”) to its biologics license application (“BLA”) seeking approval for the subcutaneous (“SC ...
FDA To Decide On Verastem's Avutometinib & Defactinib For A Subtype Of Serous Ovarian Cancer In June
The FDA has informed the company that it is not ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in ...
The FDA's decision is based on promising early data ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
The FDA decision on Donidalorsen is expected on ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
The FDA’s full approval of SYMVESS is a transformational ... were imputed as failures of limb salvage. Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver ...
This agreement ensures that the trial design, endpoints, and planned analyses meet FDA requirements and will ... do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback